AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02496936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA
Description: High monounsaturated fatty acid/MUFA oil source
Study NCT02496936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA-LA
Description: High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
Study NCT02496936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALA
Description: High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
Study NCT02496936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCn3
Description: High polyunsaturated fatty acid (omega-3)/LCn3 oil source
Study NCT01069991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education group
Description: Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
Study NCT01069991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait list control group
Description: No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
Study NCT00605761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 50 mg treatment
Study NCT00605761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 150 mg treatment
Study NCT03320421 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used.
Study NCT00848107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: sustained release tablet; BID dosing; up to 16 mg BID
Study NCT00077545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00077545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01980966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA549A
Description: IV dose
Study NCT01980966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV dose
Study NCT01980966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir [Tamiflu]
Description: Orally b.i.d, 5 days
Study NCT01404715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Basic Empathy Scale (BES) (for children)
Description: The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Pubertal Development Scale (PDS) (for children)
Description: self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
Study NCT01404715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: A single oral dose of 600 mg of imatinib
Study NCT02235038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
Study NCT02235038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
Study NCT02235038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
Study NCT01762930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
Study NCT01762930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shanchol
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
Study NCT02802449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 Hydroxy- Vitamin D3 [25 (OH) D3]
Description: Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
Study NCT02802449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Alabama Parenting Questionnaire (APQ) (for parents)
Description: The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
Study NCT04016220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
Study NCT04016220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
Study NCT03590392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik
Description: ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
Study NCT02272634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPL-001 80 mg
Description: twice daily \[BID\]
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Inventory of Callous Unemotional Traits (ICU) (for parents)
Description: 24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Child Behavior Checklist (CBCL) (for parents)
Description: The eight empirically-based syndrome scales are:~1. Aggressive Behavior~2. Anxious/Depressed~3. Attention Problems~4. Rule-Breaking Behavior~5. Somatic Complaints~6. Social Problems~7. Thought Problems~8. Withdrawn/Depressed. Higher scores indicate greater Problems.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Griffith Empathy Measure (GEM) (for parents)
Description: self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Social Responsiveness Scale (SRS) (for parents)
Description: Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
Study NCT03377205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression screws and neutralization plate
Description: Open reduction and internal fixation with screws and plate
Study NCT03377205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumed Fibular Rod System
Description: intramedullary nailing of fibula
Study NCT02874534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Treatment will consist of 15 weekly 45-minute sessions.
Study NCT00853190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
Description: Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
Study NCT03137017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: Single oral dose in one of the four cross-over trial periods.
Study NCT03137017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT7014 - Abuse Deterrent Tablet
Description: Single oral dose in one of the four cross-over trial periods.
Study NCT00455936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: gefitinib 250mg tablet/ QD daily until Progression
Study NCT00455936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
Study NCT03565250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self understanding interview
Description: semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
Study NCT03565250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self understanding interview
Description: semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
Study NCT05746013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Emulsion
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
Study NCT05746013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lipid Emulsion
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
Study NCT01653587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
Study NCT03680833 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel node detection in cervical cancer
Description: The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
Study NCT04314245 — intervention group
Intervention type: OTHER
Intervention: Active Comparator: Pathology
Description: Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
Study NCT04314245 — intervention group
Intervention type: OTHER
Intervention: Active Comparator: Clinical Diagnosis
Description: Routine clinical diagnosis and treatment of benign disease of the urinary system
Study NCT04314245 — intervention group
Intervention type: OTHER
Intervention: Active Comparator: Clinical diagnosis
Description: Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
Study NCT04314245 — intervention group
Intervention type: OTHER
Intervention: Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
Description: A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
Study NCT04311268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2D armband
Description: Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
Study NCT01628523 — intervention group
Intervention type: OTHER
Intervention: For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.
Description: Mechanical ventilation via an endotracheal tube or tracheostomy tube
Study NCT04732442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Impact Oral® Nestle, Switzerland
Study NCT04732442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Standard Oral Nutritional Support
Description: Fortimel Compact Protein® Nutricia, United Kingdom
Study NCT02626156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling gel pack
Description: Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
Study NCT02626156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooling cotton pack
Description: Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
Study NCT01804257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System
Description: The digital health offering passively collects and records medication-taking behavior and other habits of daily living
Study NCT03579693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: CoQ10 tablet
Study NCT03579693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide riboside
Description: NR tablet
Study NCT03579693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill designed to mimic coQ10 and NR
Study NCT02472587 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Study NCT02517255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging
Description: 7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
Study NCT00069134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sulfur amino acids
Description: Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
Study NCT00069134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sulfur amino acids
Description: Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
Study NCT01055717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Avenanthramide-enriched oats
Description: Single dose, 24 hour pharmacokinetic trial
Study NCT01055717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avenanthramide-enriched oats
Description: Single dose, 24 hour pharmacokinetic trial
Study NCT00751959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf
Description: Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
Study NCT00751959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curosurf
Description: Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
Study NCT02528942 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be given to study patients.
Study NCT06192472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical sclerotherapy
Description: Sclerosant will be retained within the vein
Study NCT06192472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Sodium Tetradecyl Sulphate
Description: 1% Sodium Tetradecyl Sulphate
Study NCT06192472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Tetradecyl Sulphate
Description: 3% Sodium Tetradecyl Sulphate
Study NCT06192472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Polidocanol
Description: 0.5% Polidocanol
Study NCT06192472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Polidcanol
Description: 3% Polidcanol
Study NCT02317198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT02317198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor or Prasugrel
Study NCT02705612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Study NCT04078529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 day falls prevention training
Description: Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
Study NCT04078529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise programme
Description: A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
Study NCT04078529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise programme
Description: A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
Study NCT04078529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Environmental Assessment
Description: Use of the Homefast assessment tool to reduce risk of falls at home.
Study NCT02705612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02705612 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy
Study NCT02705612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Study NCT02705612 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Internal Radiation Therapy
Study NCT02705612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Study NCT02705612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Study NCT03900728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy with needles
Description: Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
Study NCT03900728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy with beads
Description: A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
Study NCT03900728 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Adhesive disks
Description: Single-use adhesive disks without needles or beads.
Study NCT03825640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE
Description: Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.